Theravance Biopharma, Inc. Cash Provided by (Used in) Operating Activities, Discontinued Operations
Theravance Biopharma, Inc. (TBPH) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of -$184.57 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2024-03-01
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-12-31 was -$178.97M, a 6455.40% decline year-over-year.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-09-30 was -$5.21M.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-06-30 was -$1.00M.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-03-31 was $615.00K.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2022 was -$184.57M, a 761.12% decline from fiscal 2021.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2021 was $27.92M, a 126.16% increase from fiscal 2020.
- Theravance Biopharma, Inc. cash provided by (used in) operating activities, discontinued operations for fiscal 2020 was $12.34M.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$178.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$184.18M derived: sum of 2 quarters · filed 2024-03-01 | -$185.18M derived: sum of 3 quarters · filed 2024-03-01 | -$184.57M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$6.21M derived: sum of 2 quarters · filed 2023-11-09 | -$5.60M 10-Q · filed 2023-11-09 | -$2.78M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$389.00K 10-Q · filed 2023-08-09 | $2.43M derived: sum of 3 quarters · filed 2023-08-09 | |
| 2022-03-31 | $615.00K 10-Q · filed 2023-05-10 | $3.43M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $27.92M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | $25.10M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $12.34M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |